NCT07431216 2026-02-24
A Phase 1b/2a Study to Evaluate the Safety, Pharmacokinetics, and Objective Response of STAR-001 (LP-184) in Combination With Spironolactone in Supratentorial Glioblastoma at First Progression
Lantern Pharma Inc.
Phase 1/2 Not yet recruiting